Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberta Alfieri

Showing results (51-60 of 91) with videos related to

Pageof 10
Sort By:
Neoplasia (New York, N.Y.)|January 30, 2013
Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancerElena Galvani, Elisa Giovannetti, Francesca Saccani, et al.
International Journal of Molecular Sciences|January 21, 2023
A New ABCB1 Inhibitor Enhances the Anticancer Effect of Doxorubicin in Both In Vitro and In Vivo Models of NSCLCMaria Pia Adorni, Maricla Galetti, Silvia La Monica, et al.
Cancers|December 11, 2022
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma CellsRita Terenziani, Maricla Galetti, Silvia La Monica, et al.
Journal of Experimental & Clinical Cancer Research : CR|December 6, 2017
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell linesSilvia La Monica, Daniele Cretella, Mara Bonelli, et al.
Cancers|December 30, 2020
Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to OsimertinibSilvia La Monica, Claudia Fumarola, Daniele Cretella, et al.
Targeted Oncology|October 19, 2023
Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle RegulatorsFrancesco Volta, Silvia La Monica, Alessandro Leonetti, et al.
Current Pharmaceutical Design|September 15, 2012
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancerElena Galvani, Roberta Alfieri, Elisa Giovannetti, et al.
European Journal of Medicinal Chemistry|August 31, 2021
A sulfonyl fluoride derivative inhibits EGFR<sup>L858R/T790M/C797S</sup> by covalent modification of the catalytic lysineFrancesca Ferlenghi, Laura Scalvini, Federica Vacondio, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 30, 2018
Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLCRoberta Minari, Paola Bordi, Silvia La Monica, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|April 6, 2017
Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utilityAndrea Ravelli, Giandomenico Roviello, Daniele Cretella, et al.
Pageof 10

Showing results (51-60 of 91) with videos related to

Sort By:
Pageof 10
Neoplasia (New York, N.Y.)|January 30, 2013
Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancerElena Galvani, Elisa Giovannetti, Francesca Saccani, et al.
International Journal of Molecular Sciences|January 21, 2023
A New ABCB1 Inhibitor Enhances the Anticancer Effect of Doxorubicin in Both In Vitro and In Vivo Models of NSCLCMaria Pia Adorni, Maricla Galetti, Silvia La Monica, et al.
Cancers|December 11, 2022
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma CellsRita Terenziani, Maricla Galetti, Silvia La Monica, et al.
Journal of Experimental & Clinical Cancer Research : CR|December 6, 2017
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell linesSilvia La Monica, Daniele Cretella, Mara Bonelli, et al.
Cancers|December 30, 2020
Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to OsimertinibSilvia La Monica, Claudia Fumarola, Daniele Cretella, et al.
Targeted Oncology|October 19, 2023
Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle RegulatorsFrancesco Volta, Silvia La Monica, Alessandro Leonetti, et al.
Current Pharmaceutical Design|September 15, 2012
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancerElena Galvani, Roberta Alfieri, Elisa Giovannetti, et al.
European Journal of Medicinal Chemistry|August 31, 2021
A sulfonyl fluoride derivative inhibits EGFR<sup>L858R/T790M/C797S</sup> by covalent modification of the catalytic lysineFrancesca Ferlenghi, Laura Scalvini, Federica Vacondio, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 30, 2018
Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLCRoberta Minari, Paola Bordi, Silvia La Monica, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|April 6, 2017
Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utilityAndrea Ravelli, Giandomenico Roviello, Daniele Cretella, et al.
Pageof 10